OTCMKTS:BSEM BioStem Technologies (BSEM) Stock Price, News & Analysis $3.95 -0.03 (-0.75%) As of 12:17 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsSEC Filings About BioStem Technologies Stock (OTCMKTS:BSEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioStem Technologies alerts:Sign Up Key Stats Today's Range$3.91▼$4.0550-Day Range$3.00▼$4.7452-Week Range$2.25▼$8.40Volume24,483 shsAverage Volume92,484 shsMarket Capitalization$70.50 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview BioStem Technologies, Inc. is a biotechnology company focused on regenerative medicine and biologic products. Through its operating businesses, the company develops, manufactures and distributes tissue allografts derived from donated human birth tissue, including placental and amniotic tissue products intended to support wound care and tissue repair. Its product portfolio includes regenerative tissue solutions marketed for use by healthcare providers in areas such as chronic wound management, orthopedic applications and surgical procedures. The company’s products are designed for professional use and are supplied through healthcare and medical distribution channels. BioStem Technologies serves the U.S. healthcare market and has focused on expanding the commercial availability of its regenerative medicine products. Jason Matuszewski has served as the company’s chief executive officer and has been associated with its efforts to develop and commercialize biologic tissue products.AI Generated. May Contain Errors. Read More Receive BSEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioStem Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSEM Stock News HeadlinesTerminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platformSeptember 21 at 4:51 PM | financialpost.comFBioStem Secures Up To $40 Mln Committed Equity FacilitySeptember 19, 2026 | rttnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 23 at 1:00 AM | Altimetry (Ad)BioStem Technologies, Inc. announced that it expects to receive $40 million in fundingSeptember 18, 2026 | marketscreener.comMBioStem Technologies Enters Into $40 Million Committed Equity Facility with Roth Principal InvestmentsSeptember 18, 2026 | quiverquant.comQHead to Head Contrast: BioStem Technologies (OTCMKTS:BSEM) and Generate Biomedicines (NASDAQ:GENB)September 18, 2026 | americanbankingnews.comBioStem Technologies (OTCMKTS:BSEM) Trading 3.1% Higher - Here's What HappenedSeptember 12, 2026 | americanbankingnews.comBioStem Technologies Expands Hospital Access For VENDAJE And VENDAJE AC Through Vizient And PremierSeptember 4, 2026 | rttnews.comSee More Headlines BSEM Stock Analysis - Frequently Asked Questions How have BSEM shares performed this year? BioStem Technologies' stock was trading at $3.81 at the start of the year. Since then, BSEM stock has increased by 5.2% and is now trading at $4.01. How were BioStem Technologies' earnings last quarter? BioStem Technologies, Inc. (OTCMKTS:BSEM) announced its earnings results on Wednesday, August, 12th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.02. The firm had revenue of $7.90 million for the quarter, compared to analysts' expectations of $6.35 million. Read the conference call transcript. How do I buy shares of BioStem Technologies? Shares of BSEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioStem Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioStem Technologies investors own include NVIDIA (NVDA), Tesla (TSLA), Broadcom (AVGO), Advanced Micro Devices (AMD), SoFi Technologies (SOFI) and Energy Transfer (ET). Company Calendar Last Earnings8/12/2026Today9/23/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:BSEM Previous SymbolPINK:BSEM CIK1658678 Webwww.biostemtechnologies.com Phone954-380-8342FaxN/AEmployees2Year Founded2015Price Target and Rating Average Price Target for BioStem Technologies$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+125.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$292.21 million Price / Sales0.24 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares17,849,000Free FloatN/AMarket Cap$71.40 million OptionableN/A Beta0.12 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:BSEM) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioStem Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioStem Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.